ERBB2 and carcinosarcoma: Assessment of Trim24COE carcinosarcoma tumors by IHC revealed gain of vimentin, loss of E-cadherin, estrogen receptor (ER) and progesterone receptor (PR), and no over-expression of receptor tyrosine kinase erbB-2 (ERBB2) (Fig. 2b and Supplementary Fig. 2).